Sabinsa Corporation Receives the 2005 Thomas Alva Edison Patent Award

Sabinsa Corporation was awarded the Research & Development Council of New Jersey's 2005 Thomas Alva Edison Patent Award in the Enabling Technology /Small Company category for its U.S. Patent #6,849,645", method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives." The Thomas Alva Edison Patent Awards, which recognize the most revolutionary product innovations and important scientific breakthroughs originating in New Jersey, will be presented at the Council's annual fall dinner on November 3, 2005, at the North Maple Inn, Basking Ridge, NJ. Sabinsa Corporation also received this award in 2004 for ForsLean® U.S. Patent #5,804,596, "Method of preparing a forskolin composition for use in promoting lean body mass and treating mood disorders."

"We strive to provide the most innovative, functional ingredients that are supported by extensive scientific research, and this award is a wonderful recognition of our efforts in this arena," stated Dr. Muhammed Majeed, founder and CEO, Sabinsa Corporation.

Companies throughout New Jersey are invited to submit patents for consideration for the Thomas Alva Edison Patent Awards. Each patent is reviewed thoroughly by the Council, which is comprised of senior representatives from industry, academia and government. Winners are then selected based on the novelty of the invention and its contribution to the advance -ment of the relevant field, as well its utility and socio-economic value.

Tetrahydropiperine, the active compound in Cosmoperine®, is a derivative of piperine, an alkaloid naturally found in black pepper and long pepper. This patent encompasses the novel applications of Tetrahydropiperine in enhancing the bioavailability of nutrients, drugs and other active compounds. When products are formulated with Cosmoperine, poorly absorbed ingredients more easily permeate through the skin and gastrointestinal tract. For more information visit www.sabinsacosmetics.com.

OUR INNOVATION IS YOUR ANSWER®
info@sabinsa.com

Visit Sabinsa's Websites

www.sabinsa.com
www.aquasolextracts.com
www.bacopin.com
www.bioperine.com
www.boswellin.com
www.curcuminc3complex.com
www.forslean.com
www.gugulipid.com
www.garcitrin.com
www.lactospore.com
www.saberry.net
www.seleniumselect.com
www.silbinol.com
www.tetrahydrocurcuminoids.com
www.venocin.com

Dr. Vladimir Badmaev Speaks at the 2005 World Obesity & Weight Loss Congress

Dr. Vladimir Badmaev Speaks at the 2005 World Obesity & Weight Loss Congress

Vladimir Badmaev, M.D., Ph.D., vice president of medical and scientific affairs at Sabinsa Corporation, presented "The Role of Lean Body Mass in Successful Weight Management" at the World Obesity and Weight Loss Congress in Washington D.C.

Tuesday, September 13, 2005 from 3:30 - 4:15 p.m.Dr. Badmaev discussed the role of lean body mass as a key to healthy weight management. He highlighted the role of ForsLean®in increasing lean body mass and improving overall body composition. His session highlighted results from recent clinical studies,which have shown that ForsLean decreases body weight while increasing lean body mass, as well as covered ForsLean's mechanism of action, safety and toxicity and effect on key metabolic functions. Dr. Badmaev also discussed ForsLean's growing popularity internationally and highlighted some of the strongest growth opportunities for weight management products today.

Sabinsa Corporation Nominated for Product Innovation Award

MethySelene®(Methylselenocys- teine) an ingredient manufactured by Sabinsa using a patented process (US Patent #6,794,537), has been nominated for the 2005 CPhI Innovation Award.

The annual Convention of Pharmaceutical Ingredients (CPhI) is the world's leading international exhibition for pharmaceutical ingredients, intermediates and allied industries. This year's event will be held on 1, 2, and 3 November 2005. This Expo event is a significant meeting place for the global pharmaceutical manufacturing industry.



The CPhI Innovation Awards recognize and celebrate advances in technology and science. The winners will be selected at the CPhI Worldwide 2005 event in Madrid, Spain. The entries will be judged by a panel of distinguished experts from the global pharmaceutical industry. In related news, a second patent application on novel compositions of methylselenocysteine for nutraceutical use, recently received a Notice of Allowance from the USPTO.

Randomized, double-blind, placebo-controlled; 30 overweight/obese male subjects; 12 weeks, Active therapy: 250 mg ForsLean® twice daily

Serum testosterone levels and bone mass also increased signific-cantly in the treated group.

Significant Study on ForsLean® Published in "Obesity Research"

A study published in the peer reviewed medical journal "Obesity Research" reports that a twice-daily dose of 250 mg of ForsLean® significantly increased lean body mass and significantly decreased body fat in obese male subjects. This randomized, double-blind, placebo-controlled 12 weeks study examined the effect of forskolin on body composition, testosterone, metabolic rate, and blood pressure in 30 overweight and obese (BMI= 26 kg/m2) men. 15 subjects received ForsLean® (250 mg twice daily) and 15 subjects received a matching placebo. ForsLean® administration elicited favorable changes in body composition by significantly decreasing body fat percentage and fat mass as determined by DEXA, compared with the placebo group (p = 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week

Trial compared with the placebo group (p = 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p = 0.05). The actual change in serum total testosterone concentration was not significantly different among groups, but it increased 16.77 ± 33.77% in the forskolin group compared with a decrease of 1.08 ±18.35% in the placebo group.

The study was performed at the Department of Health Sports and Exercise Sciences, Applied Physiology Laboratory, University of Kansas.

Sabinsa Corporation reminds readers that the beneficial effects of ForsLean are best obtained when the supplement is used in conjunction with a sensible diet and healthy life style measures.

COSMETIC CORNER

Beauty Inside and Out: Supporting Skin Health with Nutraceutical Supplements

Sabinsa Corporation participated in the IFSCC (International Federation of Societies of Cosmetic Chemists) Annual Conference and Exhibition event in Milan, Italy. Dr. Vladimir Badmaev presented a poster titled "Tetrahydropiperine (THP), Topical Nutrient and Drug Bioavailability Enhancer", at the event.

PRODUCT ADS

Look for new product advertisements in the following publications: Chemical Market Reporter Cosmetics & Toiletries, HAPPI, Soap Perfumery & Cosmetics, Natural Products Insider Nutritional OutLook Functional Foods and Nutraceuticals